DrugsJul 21, 2026

Orforglipron: First Approval for Medical Use

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Jul 22, 2026

Abstract

In April 2026, orforglipron received its first approval in the USA for long-term weight management in adults with obesity or overweight.

Orforglipron is a non-peptide GLP-1 receptor agonist developed for weight management and type 2 diabetes treatment.
It is administered orally and used in combination with diet and physical activity.
The drug has also been submitted for regulatory review in the EU, Japan, and Canada for similar indications.
Phase III clinical evaluation is ongoing for additional conditions, including obstructive sleep apnoea and hypertension.

Simplified

Orforglipron (Foundayo™) is an orally administered, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist being developed by Eli Lilly and Co. for use in long-term weight management and for the treatment of type 2 diabetes (T2D) among other indications. In April 2026, orforglipron received its first approval, in the USA, for use in combination with a reduced-calorie diet and increased physical activity for long-term weight management in adults with obesity or adults with overweight in the presence of one or more weight-related comorbid condition. Orforglipron has also been submitted for regulatory review in the EU for long-term weight management and T2D, in Japan for long-term weight management, and in Canada for T2D. In addition to long-term weight management and T2D treatment, orforglipron is currently under phase III clinical evaluation for use in the treatment of obstructive sleep apnoea, hypertension, stress urinary incontinence in females, osteoarthritis pain and peripheral arterial disease. This article summarises the milestones in the development of orforglipron leading to this first approval for long-term weight management in adults with obesity or overweight.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

Declarations. Authorship and Conflict of interest: During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Matt Shirley is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content. Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability: Not applicable.

PubMed

Orforglipron: First Approval for Medical Use

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief